Company: STAA
Filing Date: 2025-09-26
Form Type: DEFA14A
Source: 0001193125-25-219844
Chunk: 13

Company: STAAR SURGICAL CO
Filing Date: 2025-09-26
Form: DEFA14A
Chunk 13
---
 on 90-day VWAP for period ending August 4, 2025, which was the day before announcement. Based on available brokers with current price targets as of August 1, 2025. Median premium paid of 26% across comparable transactions. Comparable transactions based on U.S. cash-only MedTech deals announced since 2015 with deal value above $500mm. ~2.0x Median Premium Paid in Comparable Transactions(3) Significant premium to STAAR stock price and significantly higher than comparable all-cash MedTech transactions. EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

Independent analysts recognize the value provided by the Alcon acquisition and that other interested parties are unlikely to provide a superior proposal “Our immediate thought is that this is the best path forward for STAA as they were likely to struggle for some time given the dynamics in the broader Chinese economy. It was unlikely that STAA's recent new mgmt. would be able to cut costs or rapidly grow their way out of STAA's immediate challenges." BTIG 8.5.25 “The takeover price represents 6x our estimated 2025 sales and is a 51% premium to Monday’s closing price or $18.49. We do not expect a higher rival bid and expect the Alcon transaction to close in the next twelve months.” Sidoti & Company 8.5.25 “There are several sizable players in the LASIK market, including BLCO (not covered), JNJ (not covered), and Zeiss (AFX:DE, not covered), which could (in our view) also be logical owners of this asset. However, we think it is unlikely that higher bid will emerge given the multiple paid and the moving pieces with the STAA story at present.” Piper Sandler 8.5.25 “ALC announced that it is acquiring STAA for $28/share. ALC expects the deal to close within 6-12 months. We do not expect additional bidders for STAA.” Wells Fargo 8.5.25 Note: Permission to use quotations neither sought nor obtained. EXECUTIVE SUMMARY | PREMIUM VALUE | STANDALONE RISKS | THOUGHTFUL EVALUATION | BROADWOOD CLAIMS

STAAR’s Net Sales have declined over the last two years. While management is aggressively executing a plan to return to growth in 2026, the fact